Furthermore, small compound inhibition of SYNJ2 decreased the invasive ability of MDA-MB-231 cells, without inhibiting the related protein SYNJ1, suggesting that SYNJ2 may be a potential druggable target to block breast cancer metastasis [83]. This evidence concerns the gene SYNJ2 and breast cancer.